• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Selva`s SLV213 Potently Inhibits Infection By the SARS-CoV-2 Omicron Variant

    BUSINESSWIRE

    Selva to Present Preclinical Data at ASV 2021 on SLV213

    BUSINESSWIRE

    Selva’s Covid-19 drug shows activity against SARS-CoV-2 variants

    CLINICAL TRAILS ARENA

    Selva Announces SLV213 has Broad Activity Against SARS-CoV-2 Variants of Concern

    BUSINESSWIRE

    Selva Announces Successful Completion of Phase 1 Clinical Study of SLV213

    BUSINESSWIRE

    Selva Announces First Dosing in Ph1 Clinical Study of SLV213

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.